

## DAFTAR PUSTAKA

1. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. *BMC Cancer*. 2010;10. doi:10.1186/1471-2407-10-337
2. Alam A. Chemotherapy Treatment and Strategy Schemes: A Review. *Open Access J Toxicol*. 2018;2(5). doi:10.19080/oajt.2018.02.555600
3. hafiz S, Amaar DS, Bastawesy DR, et al. Study the Effect of Chemotherapy on the Cardiac Function. *Int J Adv Res*. 2017;5(2):2519-2527. doi:10.21474/ijar01/3435
4. Mele D, Rizzo P, Pollina A V., et al. Cancer therapy-induced cardiotoxicity: Role of ultrasound deformation imaging as an aid to early diagnosis. *Ultrasound Med Biol*. 2015;41(3):627-643. doi:10.1016/j.ultrasmedbio.2014.11.015
5. Lustberg MB, Zareba KM. Anthracycline cardiotoxicity. *Circ Cardiovasc Imaging*. 2016;9(8). doi:10.1161/CIRCIMAGING.116.005324
6. Karim S, Bhandari U, Kumar H, et al. Doxorubicin induced cardiotoxicity and its modulation by drugs. *Indian J Pharmacol*. 2001;33(3):203-207.
7. Santos DS dos, Goldenberg RC dos S. Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy. *Cardiotoxicity*. Published online 2018:3-24. doi:10.5772/intechopen.79588
8. Puzzovivo A, Fioretti AM, Minoia C, et al. Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkin's Lymphoma: The Tei Index Evaluation. *J Pers Med*. 2022;12(2). doi:10.3390/jpm12020290
9. Shakir D. Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. *J Clin Med Res*. 2009;1(1):8-12. doi:10.4021/jocmr2009.02.1225
10. Albakri A. Chemotherapy-induced cardiomyopathy: a review of literature on

- clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy. *Med Clin Arch.* 2018;2(4):1-14. doi:10.15761/mca.1000140
11. Sawicki KT, Sala V, Prever L, et al. Preventing and Treating Anthracycline Cardiotoxicity: New Insights. *Annu Rev Pharmacol Toxicol.* 2021;61:309-332. doi:10.1146/annurev-pharmtox-030620-104842
  12. Abbas AA, Alazmii AAM. Anthracycline - Induced Cardiac Toxicity : A Clinical Review. Published online 2021. doi:10.4103/ijmpo.ijmpo
  13. Mistiaen W. Effect of Doxorubicin on Cardiac Myocytes: Role of Apoptosis, Autophagy and other Proteolytic Pathways. *Int J Cardiol Lipidol Res.* 2016;3(2):31-43. doi:10.15379/2410-2822.2016.03.02.01
  14. Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J Clin Invest.* 2014;124(2):617-630. doi:10.1172/JCI72931
  15. Timm KN, Tyler DJ. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity. *Cardiovasc Drugs Ther.* 2020;34(2):255-269. doi:10.1007/s10557-020-06941-x
  16. Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: A common factor in the complex milieu of anthracycline cardiotoxicity. *Oxid Med Cell Longev.* 2017;2017. doi:10.1155/2017/1521020
  17. Mitry MA, Edwards JG. Doxorubicin induced heart failure: Phenotype and molecular mechanisms. *IJC Hear Vasc.* 2016;10:17-24. doi:10.1016/j.ijcha.2015.11.004
  18. Rodrigues PG, Miranda-Silva D, Costa SM, et al. Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle. *Am J Physiol - Hear Circ Physiol.* 2019;316(3):H459-H475. doi:10.1152/ajpheart.00401.2018
  19. Wenningmann N, Knapp M, Ande A, et al. Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. *Mol Pharmacol.* 2019;96(2):219-232.

doi:10.1124/mol.119.115725

20. Kibudde S, Mondo CK, Kibirige D, et al. Anthracycline induced cardiotoxicity in adult cancer patients: A prospective cohort study from a specialized oncology treatment centre in Uganda. *Afr Health Sci.* 2019;19(1):1647-1656. doi:10.4314/ahs.v19i1.40
21. Nandennavar M, Sekar A, Karpurmath S. Retrospective study of chemotherapy induced cardiotoxicity from a tertiary cancer centre in South India. *Int J Res Med Sci.* 2016;4(12):5190-5195. doi:10.18203/2320-6012.ijrms20163990
22. Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. *J Support Oncol.* 2004;2(3):251-256.
23. Shaikh AS, Alam MM, Mohsin SS, et al. Risk Factors Associated with Anthracycline Induced Cardiac Dysfunction in Pediatric Patients. *World J Cardiovasc Dis.* 2014;04(07):377-383. doi:10.4236/wjcd.2014.47047
24. Ibrahim O. Anthracycline-induced cardiotoxicity. *Türk Kardiyol Dern Arş.* 2014;42(3):274-276.
25. Alkuraishy HM, Al-Gareeb AI, Al-hussaniy HA. Doxorubicin-Induced Cardiotoxicity: Molecular Mechanism and Protection by Conventional Drugs and Natural Products. *Int J Clin Oncol Cancer Res .* 2017;2(2):31-44. doi:10.11648/j.ijcocr.20170202.12
26. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. *Heart.* 2008;94(4):525-533. doi:10.1136/hrt.2007.136093
27. El-Dakroory S. Doxorubicin Cardiotoxicity in Acute Lymphoblastic Leukemia: Possible Protective Role of Grape Seed Extract Proanthocyanidins. *Br J Med Med Res.* 2014;4(13):2555-2567. doi:10.9734/bjmmr/2014/6088
28. van Dalen E. *Anthracycline-Induced Cardiotoxicity during and after Treatment for Childhood Cancer.* Vol 42.; 2006.
29. Oktem G, Ayla S, Seckin I, et al. Doxorubicin induced nephrotoxicity:

- Protective effect of nicotinamide. *Int J Cell Biol.* 2011;2011. doi:10.1155/2011/390238
30. William. Tinjauan Pustaka Patofisiologi dan Patogenesis Kardiomiopati. *FK Ukrida.* Published online 2012.
  31. Rahmadin B, Okta Safda D, Maysara F, et al. Kardiomiopati. *Fak Kedokt Univ Andalas.* 2016;(2):1-23.
  32. Domercant J, Polin N, Jahangir E. Cardio-oncology: A focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. *Ochsner J.* 2016;16(3):250-256.
  33. National Cancer Institute. Common Terminology Criteria for Adverse Events. 2017. Available from: [https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/ctcae\\_v5\\_quick\\_reference\\_8.5x11.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf). 2017;(13):1-147. doi:10.1039/DT9930001947
  34. Mizia-Stec K, Gociska A, Mizia M, et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. *Kardiol Pol.* 2013;71(7):681-690. doi:10.5603/KP.2013.0154
  35. Ahmed SN, Jhaj R, Sadasivam B, et al. Prediction of left ventricular mass index using electrocardiography in essential hypertension – A multiple linear regression model. *Med Devices Evid Res.* 2020;13:163-172. doi:10.2147/MDER.S253792
  36. Bahadır A, Kurucu N, Kadioğlu M, et al. The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study. *Turkish J Hematol.* 2014;31(1). doi:10.4274/tjh.2013.0013
  37. Maifitrianti, Sutandyo N, Andrajati R. Factor That Affect the Decline of Left Ventricular Ejection Fraction in Cancer Patients Treated With Doxorubicin At Dharmais. *Media Farm.* 2015;12:233-246.
  38. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. *J Clin Oncol.*

- 2004;22(10):1864-1871. doi:10.1200/JCO.2004.06.033
39. Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. *J Clin Oncol.* 2008;26(19):3159-3165. doi:10.1200/JCO.2007.14.1242
  40. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. *J Clin Oncol.* 2007;25(25):3808-3815. doi:10.1200/JCO.2006.10.4976
  41. Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. *J Breast Cancer.* 2013;16(2):178-183. doi:10.4048/jbc.2013.16.2.178
  42. Khattry N, Malhotra P, Grover A, et al. Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy. *Indian J Med Paediatr Oncol.* 2009;30(01):9-13. doi:10.4103/0971-5851.56329
  43. Moulin M, Piquereau J, Mateo P, et al. Sexual dimorphism of doxorubicin-mediated cardiotoxicity potential role of energy metabolism remodeling. *Circ Hear Fail.* 2015;8(1):98-108. doi:10.1161/CIRCHEARTFAILURE.114.001180
  44. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. *Cancer.* 2003;97(11):2869-2879. doi:10.1002/cncr.11407
  45. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation.* 2015;131(22):1981-1988. doi:10.1161/CIRCULATIONAHA.114.013777
  46. Chen D-S, Yan J, Yang P-Z. Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity. *Front Cardiovasc Med.* 2022;9(February):1-12. doi:10.3389/fcvm.2022.812578
  47. Jordan JH, Castellino SM, Meléndez GC, et al. Left ventricular mass change after anthracycline chemotherapy. *Circ Hear Fail.* 2018;11(7). doi:10.1161/CIRCHEARTFAILURE.117.004560

48. Jeyaprakash P, Sangha S, Ellenberger K, et al. Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: A systematic review and meta-analysis of placebo arms from randomized controlled trials. *J Am Heart Assoc.* 2021;10(6). doi:10.1161/JAHA.120.018802
49. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Develop. *Circulation.* 2009;119(14). doi:10.1161/CIRCULATIONAHA.109.192065
50. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. *Br J Cancer.* 2002;86(11):1697-1700. doi:10.1038/sj.bjc.6600346
51. Kim DY, Youn JC, Park MS, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: A 10-year multicenter cohort study. *J Cardiol.* 2019;74(2):175-181. doi:10.1016/j.jjcc.2019.02.001
52. Shyama VN. Early Cardiac Changes Due to Doxorubicin Based Chemotherapy and Radiotherapy in Early and Locally Advanced Carcinoma Breast Patients: An Observational Study. *J Nucl Med Radiat Ther.* 2015;s7. doi:10.4172/2155-9619.s7-004
53. Mobaraki M, Faraji A, Zare M, et al. Molecular mechanisms of cardiotoxicity: A review on the major side-effects of doxorubicin. *Indian J Pharm Sci.* 2017;79(3):335-344. doi:10.4172/pharmaceutical-sciences.1000235